Grupp S, Maude S, Baruchel A, et al. Tisagenlecleucel appears effective and safe in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia with high-risk cytogenetic abnormalities. 24th Congress of EHA, abstract S1618.
Interim 18F-FDG PET gevalideerd en opgenomen in richtlijn voor DLBCL
nov 2022 | Lymfoom